Compare
Innoviva, Inc. vs Ardelyx, Inc. vs Sinovac Biotech Ltd vs Arrowhead Pharmaceuticals, Inc.
| Latest fiscal year | Innoviva, Inc. INVA | Ardelyx, Inc. ARDX | Sinovac Biotech Ltd SVA | Arrowhead Pharmaceuticals, Inc. ARWR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-09-30 |
| Revenue | $411.33M | $407.32M | $386.01M | $450.82M |
| Revenue growth (YoY) | +14.7% | +22.1% | +6.8% | -45.6% |
| Gross margin | 74.8% | 90.3% (computed) | 67.9% | n/a |
| Operating margin | 39.8% | -10.1% | -127.0% | -156.9% |
| Net margin | 65.9% | -15.1% | -51.5% | -159.1% |
| Net income | $271.17M | -$61.60M | -$198.84M | -$717.13M |
| EPS (Diluted) | $3.30 | -$0.26 | -$0.83 | -$5.11 |
| Operating cash flow | $196.93M | -$42.48M | -$512.18M | -$271.95M |
| Free cash flow | $195.80M | -$43.98M | -$561.10M | -$283.94M |
| Cash & equivalents | $550.94M | $68.00M | $488.25M | n/a |
| Total assets | $1.64B | $501.60M | $8.54B | $1.74B |
| Total liabilities | n/a | $334.65M | $2.15B | n/a |
| Shareholders' equity | $1.17B | $166.95M | $6.40B | $50.50M |
| Return on year-end equity | 23.1% | -36.9% | -3.1% | n/m |
| Shares outstanding | 74.64M | 244.35M | 71.86M | 141.29M |
Revenue, most recent five fiscal years
| Fiscal year | Innoviva, Inc. | Ardelyx, Inc. | Sinovac Biotech Ltd | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $411.33M Ended 2025-12-31 | $407.32M Ended 2025-12-31 | $386.01M Ended 2025-12-31 | $450.82M Ended 2026-09-30 |
| 1 year earlier | $358.71M Ended 2024-12-31 | $333.62M Ended 2024-12-31 | $361.37M Ended 2024-12-31 | $829.45M Ended 2025-09-30 |
| 2 years earlier | $310.46M Ended 2023-12-31 | $124.46M Ended 2023-12-31 | $470.17M Ended 2023-12-31 | $3.55M Ended 2024-09-30 |
| 3 years earlier | $331.34M Ended 2022-12-31 | $52.16M Ended 2022-12-31 | $1.47B Ended 2022-12-31 | $240.74M Ended 2023-09-30 |
| 4 years earlier | $391.87M Ended 2021-12-31 | $10.10M Ended 2021-12-31 | $19.37B Ended 2021-12-31 | $243.23M Ended 2022-09-30 |